Blinatumoab公司
医学
耐火材料(行星科学)
淋巴细胞白血病
化疗
肿瘤科
急性淋巴细胞白血病
挽救疗法
内科学
作者
Hojung Choi,Jung Choi,Bo Yeon Kim,Hong An,Kyung Pyo Hong,Hee Young Shin,Hyoung Jin Kang
标识
DOI:10.1097/mph.0000000000001789
摘要
The therapeutic approach for relapsed/refractory acute lymphoblastic leukemia (ALL) remains to be a challenge. The patient was diagnosed as B-cell ALL at 6 months of age and relapsed for the second time following repeat allogeneic hematopoietic stem cell transplantation (one after first complete remission [CR1] and the other after CR2). During blinatumomab monotherapy, he developed an extramedullary relapse. Finally, the combined therapy with clofarabine, donor lymphocyte infusion, and blinatumomab induced CR of the bone marrow and extramedullary relapse. Unfortunately, the patient developed central nervous system relapse, however, this case showed a promising potential for combination therapy with clofarabine, donor lymphocyte infusion, and blinatumomab in relapsed/refractory B-cell ALL.
科研通智能强力驱动
Strongly Powered by AbleSci AI